Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel Group, Multicenter, Prospective, Open-label, Exploratory, Phase 4 Study to Evaluate the Add-on Effect of Opicapone 50 mg or Levodopa 100 mg as First Strategy for the Treatment of Wearing-off in Patients With Parkinson's Disease

NCT04821687 is registered in ClinicalTrials.gov with SK Chemicals Co., Ltd. as lead sponsor.

NCT NCT04821687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04821687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel Group, Multicenter, Prospective, Open-label, Exploratory, Phase 4 Study to Evaluate the Add-on Effect of Opicapone 50 mg or Levodopa 100 mg as First Strategy for the Treatment of Wearing-off in Patients With Parkinson's Disease
Lead sponsor
SK Chemicals Co., Ltd.
Phase
Phase 4
Overall status
Completed
Start date
June 17, 2021
Completion date
August 18, 2022
Enrollment
169 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease